Vaccines based on messenger ribonucleic acid (mRNA) created headlines in December 2020 for being the first highly efficacious SARS-CoV-2 prophylactics to receive emergency use authorization (EUA) from the US Food and Drug Administration (FDA). Within a couple months of the virus’s gene sequence being published (1), Pfizer and BioNTech were ready with their vaccine candidate (2), and in less than a year, the vaccine was approved for administration in adults. EUA for Moderna’s mRNA vaccine followed soon after. The rapidity…